Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.54 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.52 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.50 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.50 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.50 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1469765 | 1.00 | FBP1 (0.56) | FBP1P2RY2P2RY4P2RY14MACROD2 | |
| SCHEMBL30748277 | 1.00 | FBP1 (0.56) | FBP1P2RY2P2RY4P2RY14MACROD2 | |
| SCHEMBL5063689 | 0.98 | FBP1 (0.54) | FBP1P2RY2P2RY4P2RY14MACROD2 | |
| SCHEMBL5063695 | 0.98 | FBP1 (0.54) | FBP1P2RY2P2RY4P2RY14MACROD2 | |
| SCHEMBL23723111 | 0.97 | FBP1 (0.59) | FBP1P2RY2P2RY4P2RY14MACROD2 | |
| SCHEMBL31540137 | 0.97 | FBP1 (0.59) | FBP1P2RY2P2RY4P2RY14MACROD2 | |
| SCHEMBL17581993 | 0.97 | FBP1 (0.59) | FBP1P2RY2P2RY4P2RY14MACROD2 | |
| SCHEMBL5059685 | 0.95 | FBP1 (0.58) | FBP1P2RY2P2RY4P2RY14MACROD2 | |
| SCHEMBL5063577 | 0.95 | FBP1 (0.58) | FBP1P2RY2P2RY4P2RY14MACROD2 | |
| SCHEMBL24474280 | 0.86 | FBP1 (0.51) | FBP1P2RY2P2RY4P2RY14MACROD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207302-A1 | ANTIVIRAL COMPOUNDS, METHODS FOR THE MANUFACTURING OF COMPOUNDS, ANTIVIRAL PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR THE ORAL TREATMENT OF CORONAVIRUS INFECTION AND RELATED DISEASES THEREOF | CALIXTO JOAO BATISTA (BR) | 2024-06-27 | — | — | US | disclosed |
| US-20240074434-A1 | COMPOSITION INCLUDING EFFERVESCENT AGENTS, BIOSTIMULANT, NUTRIENT, AND PESTICIDE | ROBBINS JEFFREY HANSON (US) | 2024-03-07 | — | — | US | disclosed |
| US-20240065262-A1 | COMPOSITION INCLUDING EFFERVESCENT AGENTS, BIOSTIMULANT, NUTRIENT, AND PESTICIDE | ROBBINS JEFFREY HANSON (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4314001-A1 | ANTIVIRAL COMPOUNDS, METHODS FOR THE MANUFACTURING OF COMPOUNDS, ANTIVIRAL PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR THE ORAL TREATMENT OF CORONAVIRUS INFECTION AND RELATED DISEASES THEREOF | Calixto, João Batista (BR) | 2024-02-07 | — | — | EP | disclosed |
| US-20230265444-A1 | GENE-EDITING IN CANNABIS PLANT | CANOPY GROWTH CORPORATION (CA) | 2023-08-24 | — | — | US | disclosed |
| WO-2023154183-A1 | COMPOSITION INCLUDING EFFERVESCENT AGENTS, BIOSTIMULANT, NUTRIENT, AND PESTICIDE | ROBBINS JEFFREY (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230172194-A1 | COMPOSITION INCLUDING EFFERVESCENT AGENTS, BIOSTIMULANT, NUTRIENT, AND PESTICIDE | ROBBINS JEFFREY HANSON (US) | 2023-06-08 | — | — | US | disclosed |
| US-20220272987-A1 | COMPOSITION INCLUDING EFFERVESCENT AGENTS, BIOSTIMULANT, NUTRIENT, AND PESTICIDE | ROBBINS JEFFREY H (US) | 2022-09-01 | — | — | US | disclosed |
| WO-2017182634-A1 | RNA ENCODING A TUMOR ANTIGEN | CUREVAC AG (DE) | 2017-10-26 | — | — | WO | disclosed |
| US-20170191042-A1 | CYTOKININ SYNTHASE ENZYMES, CONSTRUCTS, AND RELATED METHODS | DOW AGROSCIENCES LLC (US) | 2017-07-06 | — | — | US | disclosed |
| US-9617524-B2 | Cytokinin synthase enzymes, constructs, and related methods | DOW AGROSCIENCES LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160076010-A1 | CYTOKININ SYNTHASE ENZYMES, CONSTRUCTS, AND RELATED METHODS | CORTEVA AGRISCIENCE LLC | 2016-03-17 | — | — | US | disclosed |
| EP-2265624-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | Centre National de la Recherche Scientifique (FR) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009115694-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-09-24 | — | — | WO | disclosed |
| US-7385051-B2 | Fluorescent N2,N3-etheno-purine (2′-deoxy) riboside derivatives and uses thereof | BAR-LLAN UNIVERSITY (IL) | 2008-06-10 | — | — | US | disclosed |
| US-20060166248-A1 | Fluorescent N2, N3-etheno-purine (2'deoxy) riboside derivatives and uses thereof | BAR-ILAN UNIVERSITY (IL) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166248-A1 | Fluorescent N2, N3-etheno-purine (2'deoxy) riboside derivatives and uses thereof | NUDT1, NT5C2, DUT | FBP1 1844/4885P2RY2 115/4885P2RY4 131/4885 |
| US-20240207302-A1 | ANTIVIRAL COMPOUNDS, METHODS FOR THE MANUFACTURING OF COMPOUNDS, ANTIVIRAL PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR THE ORAL TREATMENT OF CORONAVIRUS INFECTION AND RELATED DISEASES THEREOF | RNGTT, ACE2, ACE | FBP1 1065/4885P2RY2 647/4885P2RY4 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.